GlassScriptPhysician profile
Anmol Singh
NPI 1720510100
$5,546.54
in general payments reported to CMS, 2019-2025
52 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $392 · 2023: $545 · 2024: $3,093 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $75.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,624.03 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $75.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,805.71 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $488.06 | 2023-2024 | Zepzelca |
| Daiichi Sankyo INC. | $322.80 | 2023-2025 | Enhertu, Injectafer |
| Secura Bio, INC. | $233.50 | 2022 | |
| Janssen Biotech, INC. | $229.53 | 2023-2025 | Darzalex, Akeega, Erleada |
| Pfizer INC. | $182.34 | 2023-2025 | |
| Genzyme Corporation | $164.86 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $133.95 | 2023-2024 | Keytruda, Lynparza |
| Rigel Pharmaceuticals, INC. | $132.92 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $130.93 | 2022-2024 | Libtayo |
| Lilly USA, LLC | $127.40 | 2021-2025 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $116.33 | 2023-2024 | Calquence, Enhertu, Imfinzi |
| Genentech USA, INC. | $109.39 | 2023-2025 | Tecentriq, Itovebi, Tecentriq Hybreza |
| Takeda Pharmaceuticals U.S.A., INC. | $107.89 | 2024 | Fruzaqla, Alunbrig, Iclusig |
| Exelixis INC. | $75.99 | 2024 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anmol Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.